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TO THE READER 
Prime Minister Sipilä’s Government Programme states as follows: “The Government 
will implement a rational pharmacotherapy implementation programme aimed at 
improving the implementation of comprehensive patient care, improving people’s 
functional capacity, and creating conditions for cost-effective pharmacotherapy from 
the perspectives of the patient and society.” 
On 18 January 2016, the Ministry of Social Affairs and Health appointed a steering 
group for the Rational Pharmacotherapy Action Plan to implement the policy outlined 
in the Government Programme. The assignment of the steering group was to prepare 
the Action Plan, drawing on existing projects to enhance a rational approach towards 
pharmacotherapy, and to determine objectives for promoting rational 
pharmacotherapy. Five working groups were set up under the auspices of the steering 
group. Their operations and compositions are described in Appendices 1 and 2, 
respectively. Each working group included a designated contact for data 
management. In addition, an ad hoc working group on data management was set up 
for the spring of 2017 to take stock of existing projects relating to data management 
and digital service models, with a view to ensuring that these were paying attention to 
aspects relevant to rational pharmacotherapy.  
The key objectives of the Action Plan are related to the safety, quality, effectiveness 
and cost-effectiveness of pharmacotherapy. A further purpose of the Action Plan is to 
promote the Government Programme’s objectives of narrowing disparities in health 
and wellbeing and managing costs. 
This final report describes the Rational Pharmacotherapy Action Plan and its 
objectives to be achieved by 2022. At the same time as the final report, the working 
groups are also publishing their own reports, which focus on different themes and are 
referenced in this final report. 
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The Action Plan identifies the following key themes relating to the use of medicines: 
1. Promoting rational pharmacotherapy by means of comprehensive 
medication management; 
2. Effective pharmaceutical services in new health and social services 
structures; 
3. Assessing therapeutic and economic value and tapping into the data 
resources available in health and social services; 
4. Promoting research conducted in support of rational pharmacotherapy; 
5. Advancing pharmaceutical innovation activities. 
The policies relating to these themes are discussed in Chapters 1–5, divided into 
objectives for national implementation, services organisers, services providers, 
healthcare and social welfare professionals, and medicine users. Each of the policies 
outlined in chapter titles is followed by reasoning as to why it was considered 
important to highlight as part of the Rational Pharmacotherapy Action Plan. After that, 
there is an overview of objectives and vision for the future, ending with the objectives 
set out for 2022. Each chapter also describes the studies commissioned in the course 
of preparing the Rational Pharmacotherapy Action Plan and makes references to 
working group reports, which open up their activities in further detail. This report does 
not specify any parties responsible for the measures, because responsibilities for 
many of the measures may be assigned to several parties and specifying 
responsibilities may be difficult due to changes in operating environments. The hope 
is for the parties operating in the pharmaceutical sector to feel ownership of the 
objectives and to reflect on the means available to them to achieve these objectives in 
their own operations.  
The work carried out as part of the Rational Pharmacotherapy Action Plan is based on 
the policies outlined in the Medicines Policy 2020, which states that “rational 
pharmacotherapy and good medication safety enhance the wellbeing of the 
population, improve public health and decrease the healthcare expenditures” (Ministry 
of Social Affairs and Health 2011). In addition to the policies outlined in the Medicines 
Policy 2020, other resources used in drafting the Action Plan include existing research 
data and the policies outlined by working groups dealing with development of 
pharmacy activities and other pharmaceutical services.  
The Rational Pharmacotherapy Action Plan was drawn up in a situation where 
forthcoming health and social services structures and legislation governing the 
organisation of services were only being drafted. Nevertheless, it was expedient also 
to explore promotion of rational pharmacotherapy in future health and social services 
structures, rather than limiting the analysis to the current situation. 
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BACKGROUND 
In recent years, the value of pharmaceutical sales has increased by about two to 
three per cent per year. Finnish patients and healthcare services have access to a 
wide and modern variety of medicines, while Finnish healthcare and social welfare 
services, pharmaceutical services included, are of the highest level in international 
terms. While the rational use of medicines makes it possible to improve people’s 
functional and working capacity, use of pharmaceuticals also involves problems. It 
has been estimated that adverse patient safety events, with a significant proportion 
relating to medication, result in the death of 700–1,700 hospital patients per year in 
Finland (Pasternack 2006). Furthermore, it is known that only about 50% of drug 
therapies are carried out as prescribed by the doctor (WHO 2003). 
According to a study published by the National Audit Office (2017), for frequent users 
of primary healthcare services there are deficiencies in the organisation of the 
services provided and the procedures in place. Smoother exchange and more efficient 
use of client data, complete with integration of patient record systems, would serve 
the quality and management of medications as a whole when identifying the group of 
frequent service users and planning their clinical pathways. These clients’ individual 
therapies should be planned, implemented and monitored in a coordinated, evidence-
based, performance-oriented and multidisciplinary manner, involving the individuals in 
the process. From the perspective of comprehensive medication management, 
special attention should be paid to clients with multiple illnesses and medications and 
high medicine costs. 
Since the 1990s, the growth in medicine costs has mainly been curbed by means 
relating to medicine prices and users’ co-payments. The underlying reasons for the 
growing costs include the fact that new pharmaceuticals enter the market at 
constantly increasing prices. Consequently, it is necessary to identify measures to 
safeguard Finnish patients’ equal rights to access safe, efficient and reasonably 
priced medications, while ensuring the sustainability of public healthcare systems. 
The most recent amendments to the medicine reimbursement system entered into 
force at the beginning of 2017. As a result of these changes, rational 
pharmacotherapy shall be promoted through measures targeted at prescribing and 
dispensing medicines.  
Rational pharmacotherapy is safe, effective, cost-effective, equitable and of high 
quality. The core contents of the objectives specified in the Rational Pharmacotherapy 
Action Plan are explained in Figure 1 below, with special focus on the patient 
perspective. The prerequisites of successful pharmacotherapy will improve when 
patients participate in the planning and implementation of their own pharmacotherapy 
as partners, when the regimen of medications is jointly agreed, and when patients 
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receive support in the use of medicines. Rational pharmacotherapy and 
pharmaceutical services form a coordinated whole, where management is based on 
knowledge. 
Figure 1. Objectives of the Rational Pharmacotherapy Action Plan viewed from the patient perspective. 
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1 Pharmacotherapy and 
pharmaceutical services will be 
managed by knowledge at national 
and regional levels and in service 
units 
Objective for steering bodies (central government, service organiser, service 
provider) 
‘Management by knowledge’ refers to making use of expertise and the best 
information available when steering and making decisions on pharmacotherapy 
and pharmaceutical services. The planned health and social services reform will 
reinforce national steering mechanisms. At the same time, the legislation 
currently being drafted specifies that the service organiser is responsible for 
ensuring that service providers cooperate with each other to guarantee clients’ 
access to integrated services. It is therefore necessary to establish the types of 
information the steering bodies will require and how to collect and make use of 
this information in an efficient manner. Furthermore, it is necessary to decide 
the best way to refine and make use of the information accumulated in the data 
resources of health and social services as part of steering and making 
decisions relating to pharmaceutical services and pharmacotherapy. 
Pharmacotherapy and pharmaceutical services will be steered centrally at a national 
level based on up-to-date information and shared objectives. The existing registers 
and statistics will form the foundation for steering as well as monitoring the use of 
medicines. The decisions made by various organisations and healthcare professionals 
at the different stages of the pharmacotherapy process will be based on up-to-date 
care recommendations, the medicine reimbursement system, the range of national 
healthcare services, national objectives for steering pharmacotherapy, and monitoring 
of care outcomes. Equitability between individuals in terms of access to medicines will 
be safeguarded by means of evidence-based national policies and regional 
guidelines. Operating models implemented in healthcare and social welfare service 
units will have been agreed at a national level, also involving medicine users in the 
process, in order to bring medication data up to date, to identify medicine users 
benefiting from medication review, to target medication review services appropriately, 
and to promote a multidisciplinary cooperation culture responsive to the needs of 
medicine users. 
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The data resources of health and social services and their quality improvement will be 
ensured at a national level as the health and social services structures are reformed. 
The health and social services data resources refer to healthcare registers, patient 
record systems, data accumulated in biobanks and in the National Archive for Health 
Information (Kanta services), etc. National bodies, service organisers and service 
providers will possess sufficient expertise and competence to apply and make use of 
the accumulated data as part of steering rational pharmacotherapy and developing 
their own operations. The aim is to put these data resources to better use as part of 
management, decision-making, allocation of resources and steering of medicine use 
and pharmaceutical services. The indicators created in support of the health and 
social services reform, including the KUVA indicators and the Information Package for 
Pharmaceutical Services prepared by the Ministry of Social Affairs and Health and the 
Finnish Innovation Fund Sitra, will supplement existing sources of information, 
providing information on the use and costs of health and social services, etc. 
The national feedback systems and research and development (R&D) projects 
relating to medicines and use of medicines will produce information, facilitating the 
development of procedures used in service units and by various professionals within 
healthcare and social welfare services. R&D activities will provide information required 
in steering pharmacotherapy and pharmaceutical services, while research will also be 
utilised as part of steering and decision-making processes. Cooperation between 
researchers and decision-makers will increase. Cooperation between researchers will 
reduce overlapping work, while implementation of more extensive collaborative 
research projects will be enabled as a result of funding allocated to research into 
rational pharmacotherapy. 
The infrastructure and systems of health and social services data resources will be in 
place, enabling the production of real-world evidence (RWE) on pharmacotherapies 
and pharmaceutical services to meet the needs of decision-makers. Furthermore, 
efforts will be made to promote the fulfilment of the significant research and innovation 
potential relating to health and social services data resources, which may open up 
possibilities for increasing pharmaceutical research in Finland. The aim is to improve 
access to health and social services data resources for R&D purposes, with due 
consideration for the data protection of individuals. The required patient data will have 
been recorded in a comprehensive, high-quality and consistent format, enabling 
nationwide utilisation of such data. 
National assessments of the therapeutic and economic value of medicines will steer 
the use of new hospital medicines in particular. Such assessments will support 
decision-making, procurement procedures and determination of the real prices 
payable for medicines and related procedures. Additional evidence on the costs, 
consumption and outcomes of the assessed medicines, allocation of their use and 
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therapy processes will be regularly collected from health and social services data 
resources. Furthermore, there will be policies in place to determine who will collect 
such additional evidence and how it will be utilised in policies relating to the use of 
medications and, as far as possible, in procurement procedures. 
In 2014, the Government published its Health Sector Growth Strategy for Research 
and Innovation Activities. The strategy includes key recommendations for measures in 
order to develop research and innovation activities systematically while also 
increasing investments and generating economic growth in the health sector. To 
support its implementation, a Roadmap for the Growth Strategy for Health Sector 
Research and Innovation Activities was published in 2016. 
The pharmaceutical industry and pharmaceutical innovations form a key part of the 
Growth Strategy and the Roadmap. Pharmaceutical development and, in particular, 
clinical trials will increase pharmaceutical competencies and resources in healthcare. 
Pharmaceutical R&D activities will be focused on areas that offer competitive 
conditions. Agility, the high quality of information derived from healthcare services and 
networking abilities will be further consolidated in support of pharmaceutical research. 
Information on the prevalence and treatment of disease, care outcomes and their 
contributing factors will not only be collected and put to use in healthcare 
development, steering and management processes, but also in pharmaceutical 
development. Finnish pharmaceutical research will be supported using the best 
identified means, in order to improve possibilities for research conducted in pursuit of 
pharmaceutical innovations, as well as for manufacturing and commercialisation. This 
is expected to create new jobs and increase pharmaceutical exports and foreign 
investments in Finland. 
OBJECTIVES TO BE ACHIEVED BY 2022 
• Steering will be based on national policies, evidence-based care 
recommendations and other jointly agreed objectives. National operating 
models will have been drawn up in order to bring medication data up to 
date, to identify medicine users benefiting from medication review, and 
to target medication reviews. 
• The existing data resources will be put to active use in steering the 
implementation of pharmacotherapy and in operational development at 
national, regional and service unit levels. Competencies will be sufficient 
to make use of information. 
• The data accumulated in health and social services data resources will 
be nationally comprehensive, of high quality, in a usable format and 
easily accessible in support of management by knowledge.  
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• R&D activities relating to rational pharmacotherapy will have been 
integrated as part of the health and social services system, while 
research information will be utilised when steering the operations. 
• Decision-making processes and procurement procedures will be 
supported by national assessments of the therapeutic and economic 
value of medicines. 
REPORTS AND STUDIES INCLUDED IN THE ACTION PLAN 
Pelkonen L, Rannanheimo P, Anttila V-J, Komulainen J, Koskinen H, Leipälä J, ym. 
Miten lääkkeiden hoidollisen ja taloudellisen arvon arviointi tulisi järjestää Suomen 
sosiaali- ja terveydenhuollossa? Rationaalisen lääkehoidon toimeenpano-ohjelman 
asiantuntijaryhmän selvitys. Sosiaali- ja terveysministeriön raportteja ja muistioita 
2017:31.  
[Pelkonen L, Rannanheimo P, Anttila V-J, Komulainen J, Koskinen H, Leipälä J, et al. 
How should the assessment of the therapeutic and economic value of medicines be 
organised in Finland's healthcare and social welfare services? Study by an expert 
group for the Rational Pharmacotherapy Action Plan. Reports and Memorandums of 
the Ministry of Social Affairs and Health 2017:31.] 
Available in Finnish at: http://urn.fi/URN:ISBN:978-952-00-3881-3 
Tutkimustieto hyötykäyttöön: Rationaalisen lääkehoidon tutkimusstrategia 2018–2022. 
Sosiaali- ja terveysministeriön raportteja ja muistioita 7/2018.  
[Effective use of research data: Research strategy for rational pharmacotherapy 
2018–2022. Reports and Memorandums of the Ministry of Social Affairs and Health 
7/2018.] 
Available in Finnish at: http://urn.fi/URN:ISBN:978-952-00-3905-9 
Palva E. Esiselvitys: Kansallinen lääkekehityskeskus. Sosiaali- ja terveysministeriön 
raportteja ja muistioita 2017:15.  
[Palva E. Preliminary report: National Pharmaceutical Development Centre. Reports 
and Memorandums of the Ministry of Social Affairs and Health 2017:15.] 
Available in Finnish at: http://urn.fi/URN:ISBN:978-952-00-3865-6 
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2 Service organisers will be in 
charge of pharmacotherapy and 
pharmaceutical services as a 
whole 
Objective for service organisers 
The health and social services reform currently being prepared intends to 
transfer the responsibility for organising health and social services to new 
counties, simplify multisource financing of health and social services, and 
enable patients to choose service providers from the public, private and third 
sectors. Pharmaceutical services offer medicines and services to all parties 
involved in health and social services and contribute to enabling the 
implementation of integrated care pathways and rational pharmacotherapy. The 
Rational Pharmacotherapy Action Plan focused special attention on hospital 
pharmacy activities and the rational pharmacotherapy process in the 
forthcoming health and social services structures. 
In the future health and social services structures, service organisers will be 
responsible for ensuring that citizens will receive the healthcare and social welfare 
services that they require. Pharmacotherapy is part of this whole: in other words, 
service organisers will be in charge of pharmacotherapy and pharmaceutical services 
as a whole, coordinating medication safety and medicines information, and monitoring 
the safety of pharmacotherapy and the effectiveness of pharmaceutical services. 
Furthermore, services will be adapted to meet the needs of each client by creating an 
integrated whole known as a care pathway, which covers timely access to 
pharmacotherapy and comprehensive medication management. Service organisers 
will thus ensure an unbroken pharmacotherapy process for the residents of their 
respective regions. The role of pharmaceutical services is to contribute to enabling the 
implementation of rational pharmacotherapy. Each service organiser will possess 
sufficient pharmaceutical competencies within its organisation to be capable of 
planning and managing pharmaceutical services as a whole, while also understanding 
the pharmacotherapy processes in place in provider organisations. Patients’ 
representatives will be involved in planning pharmacotherapy processes. 
Service organisers will contribute to ensuring the sufficient availability of community 
pharmacy services. Community pharmacies will operate as part of the healthcare and 
social welfare service chain and individual clients’ care pathways. When dispensing 
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medicines, pharmacies will verify that pharmacotherapy is appropriate, while providing 
support for use of medicines and monitoring of pharmacotherapy. 
OBJECTIVES TO BE ACHIEVED BY 2022 
• Regions will have effective structures in place to ensure multidisciplinary 
cooperation between various stakeholders and steering of 
pharmacotherapy. 
• Pharmaceutical services will operate on the basis of knowledge, while 
operations across organisational boundaries will be managed and 
coordinated as a whole.  
• Regional steering systems to improve the quality of pharmacotherapy 
will be in place and put to use. Efforts will be made to monitor and 
develop the safety of pharmacotherapy and the effectiveness of 
pharmaceutical services. 
• Service organisers will ensure that the principles of rational 
pharmacotherapy are being realised in healthcare and social welfare 
services as a whole. 
REPORTS AND STUDIES INCLUDED IN THE ACTION PLAN 
Lääkehuolto sote-toimintaympäristössä. Työryhmän raportti. Sosiaali- ja 
terveysministeriön raportteja ja muistioita 6/2018.  
[Pharmaceutical services in the operating environment of health and social services. 
Working group report. Reports and Memorandums of the Ministry of Social Affairs and 
Health 6/2018.] 
Available in Finnish at: http://urn.fi/URN:ISBN:978-952-00-3903-5 
Kvarnström K. Selvitys Ruotsin lääketyöryhmien toiminnasta ja niiden toiminnan 
vaikuttavuudesta sekä ehdotukset Suomen sote-järjestämisvastuussa olevien 
alueiden lääketyöryhmien toteuttamisesta. Julkaisematon raportti, Sosiaali- ja 
terveysministeriö 2016. 
[Kvarnström K. A study on the operations of Swedish Drug and therapeutics 
committee and the effectiveness of their actions, with proposals for implementing 
regional working groups on pharmaceuticals responsible for organising health and 
social services in Finland. Unpublished report, Ministry of Social Affairs and Health 
2016.] 
Kärkkäinen R. Euroopan unionin oikeuden asettamat reunaehdot sote-
lääkehuoltoratkaisuille – selvitys rajapinnoista lääkelain ja lääkedirektiivin välillä. 
Julkaisematon raportti, Sosiaali- ja terveysministeriö 2016.  
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[Kärkkäinen R. The parameters imposed by European Union law on the solutions of 
pharmaceutical services as part of health and social services – A study on the 
interfaces between the Finnish Medicines Act and the EU Directive on medicinal 
products. Unpublished report, Ministry of Social Affairs and Health 2016.] 
Torniainen K. Esiselvitys: Sairaala-apteekkitoiminta nykyisissä ja tulevissa sote-
rakenteissa. Sosiaali- ja terveysministeriön raportteja ja muistioita 13/2018.  
[Torniainen K. Preliminary report: Hospital pharmacy in current and future service 
systems. Reports and Memorandums of the Ministry of Social Affairs and Health 
13/2018.] 
Available in Finnish at: http://urn.fi/URN:ISBN:978-952-00-3913-4 
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3 Pharmacotherapy will be managed 
as a whole 
Objective for healthcare and social welfare service units 
There is plenty of research data available on problems in the rational use of 
medicines. Key challenges for implementing rational pharmacotherapy include 
comprehensive medication management and the lack of up-to-date information 
on individual patients’ medications within healthcare and social welfare 
services. The situation will be improved through digital solutions, in particular 
the national medication list included in Kanta services. In addition, it is 
necessary to put new operating models into efficient use at the levels of 
teamwork, organisations and structures. Being in charge of providing adequate 
resources and defining responsibilities, each organisation’s managerial staff 
play a key role in introducing operating models that promote rational 
pharmacotherapy. The Rational Pharmacotherapy Action Plan places a special 
emphasis on the role of the management in healthcare and social welfare 
service units, because the national operating models geared towards bringing 
medication data up to date, identifying medicine users benefiting from 
medication review and targeting medication reviews will be integrated as part of 
the operations of service units. 
Multidisciplinary and cross-organisational cooperation aims to manage medications as 
a whole at different stages of the pharmacotherapy process and as part of individual 
patients’ integrated care pathways. Various national operating models, specified at 
regional and organisational levels, will ensure a rational approach towards 
pharmacotherapy, including medication safety, at all stages of the pharmacotherapy 
process. Channels for communication and information sharing between different 
professionals and organisations will be in place at different phases of the service 
chain. Close cooperation between healthcare and social welfare services is 
particularly necessary in cases where patients cannot afford to pay for the 
medications that they need, require especially expensive medications, or have high 
total need for healthcare and social welfare services. 
The management of healthcare and social welfare service units will ensure that the 
units are equipped with secure electronic tools that support professionals in their work 
at different stages of the pharmacotherapy process. The management of service units 
will further ensure that up-to-date data included in electronic decision support systems 
is taken into account as part of making decisions on and monitoring 
pharmacotherapy. Healthcare and social welfare professionals will take care of 
updating and documenting data relating to medications and its transfer between 
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different organisations, where this is not done via Kanta services. Improved 
coordination of prescription practices and pharmacotherapy will prevent problems 
identified in pharmacotherapy. 
The managerial staff of healthcare and social welfare service units will be responsible 
for ensuring that their own unit-based medicines management plan describes the 
operating models geared towards bringing medication data up to date, identifying 
patients benefiting from medication review, targeting the most demanding medication 
review services appropriately, and promoting a multidisciplinary cooperation culture 
responsive to the needs of medicine users. Multidisciplinary cooperation across 
organisational boundaries will make it possible to identify and solve pre-existing 
pharmacotherapy problems. Pharmacotherapy will be carried out in keeping with the 
operating models described in unit-based medicines management plans. 
Multidisciplinary cooperation will be put to more coordinated use in bringing 
medication data up to date and in reviewing and monitoring medication. Patients’ 
representatives will be involved in planning the deployment of the operating models at 
a regional level. 
Client care plans and up-to-date medication lists will be widely in place at a national 
level. The national medication list will be based on national information system 
services, which are used to retrieve, record and store patient data and to ensure 
consistent nationwide operating models and principles for handling patient records. 
The medication list is based on the idea that all data on medication is stored in a 
single location accessible to all bodies and individuals involved in the 
pharmacotherapy process. The medication list can be viewed in an identical format by 
everyone (except for any information subject to refusals of disclosure), and all 
involved may update the data. One of the biggest obstacles to implementation of 
rational pharmacotherapy has been the lack of up-to-date information on individual 
patients’ medication within healthcare and social welfare services. With the 
introduction of the national medication list, it will become easier for healthcare 
professionals to check the medication as a whole and carry out medication reviews in 
multidisciplinary cooperation. Instead of requiring specific maintenance, the 
medication list will be updated whenever structured medication data is stored in 
national information system services, regardless of the organisation that originally 
produced the data. Medicine users will also receive support in recording their over-
the-counter (OTC) medicines and other medicinal products available without 
prescription in the My Kanta Pages service, making information on their use available 
to all healthcare and social welfare professionals. Patient record systems and their 
various in-built decision support systems and electronic databases will support the 
implementation of safe pharmacotherapy. 
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A self-supervision plan will be in place in each service unit providing healthcare and 
social welfare services, including the unit’s pharmacotherapy plan. The service unit’s 
management will be responsible for conducting medication safety audits as part of 
self-supervision. The safety of pharmacotherapy processes and practices in place in 
housing and home care services should be verified regularly in a manner at least 
equivalent to institutional settings. 
Professionals must possess sufficient knowledge and skills to carry out 
pharmacotherapy appropriately, to monitor and assess its effects, to provide medicine 
users with medication and self-management counselling, and to use digital tools in 
support of their own work. The level of training in pharmacotherapy provided for 
different healthcare and social welfare professionals will match the duties of each 
professional group, while being consistent in different training units and 
multidisciplinary throughout the country. 
Implementing the principles of rational pharmacotherapy requires strategic 
management of the competencies and development of service units, and 
understanding of safety and security culture. Any deviations relating to 
pharmacotherapy should be identified, reported and analysed. Healthcare and social 
welfare professionals will develop in their work and change their operating methods 
with support from their own service unit’s operational development and the in-house 
training provided. Professionals’ self-motivated continuing training will not be enough 
on its own to guarantee development of pharmacotherapy competencies and 
operating methods in service units. This also requires long-term training courses and 
research (Government Proposal 15/2017 for the Act on Organising Health and Social 
Services, section 16, section 39). 
OBJECTIVES TO BE ACHIEVED BY 2022 
• The national operating models geared towards bringing medication data 
up to date, identifying medicine users benefiting from medication review, 
and targeting medication reviews will be widely used in healthcare and 
social welfare service units.  
• Cooperation between healthcare and social welfare service units and 
pharmacies will be effective. Effective digital channels that function well 
will be in place for communication between different professionals and 
organisations.  
• Electronic decision support systems and reliable sources of medicines 
information will be widely in place and used to manage and prevent 
medication risks. Service units will ensure that the opportunities brought 
about by digitalisation are available to healthcare and social welfare 
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professionals and that they possess sufficient competencies to make 
use of these. 
• Multidisciplinary cooperation responsive to patient needs will be put to 
more coordinated use in reviewing and monitoring medication. 
• Pharmacotherapeutic competencies and medication safety will be 
included in basic, advanced and continuing training in healthcare and 
social services at a level suited to the duties of each professional group. 
• Patients’ medications and care outcomes will be recorded consistently in 
healthcare and social welfare service units. Special attention will be paid 
to diseases of significance to public health and the economy. 
REPORTS AND STUDIES INCLUDED IN THE ACTION PLAN 
Merikoski M, Jyrkkä J, Auvinen K, Enlund H, Kumpusalo-Vauhkonen A, Liukkonen T, 
ym. Iäkkäiden Lääkehoidon Moniammatillinen Arviointi (ILMA). Vaikutukset kotihoidon 
asiakkaiden lääkitykseen, toimintakykyyn ja elämänlaatuun sekä terveys- ja 
hoivapalveluiden käyttöön. Sosiaali- ja terveysministeriön raportteja ja muistioita 
2017:34.  
[Merikoski M, Jyrkkä J, Auvinen K, Enlund H, Kumpusalo-Vauhkonen A, Liukkonen T, 
et al. The Finnish Interprofessional Medication Assessment (FIMA) for Older People. 
Effects on medication, functional capacity, quality of life and use of health and home 
care services in home care patients. Reports and Memorandums of the Ministry of 
Social Affairs and Health 2017:34.] 
Available in Finnish at: http://julkaisut.valtioneuvosto.fi/handle/10024/80566 
Hautala H. Rationaalisen lääkehoidon ohjelmien kansainvälinen vertailu – Ruotsi, 
Tanska, Skotlanti, Suomi. Julkaisematon raportti, Sosiaali- ja terveysministeriö 2016. 
[Hautala H. International comparison of rational pharmacotherapy programmes – 
Sweden, Denmark, Scotland, Finland. Unpublished report, Ministry of Social Affairs 
and Health 2016.] 
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4 Healthcare and social welfare 
professionals will implement 
rational pharmacotherapy 
Objective for healthcare and social welfare professionals 
Prescribers of medicines play a key role in ensuring rational pharmacotherapy: 
is pharmacotherapy safe, effective, cost-effective, equitable and of high quality 
for every medicine user? Doctors are responsible for planning medications as a 
whole, involving medicine users in the process, as well as for agreeing on the 
monitoring and self-management of medications with users. Other healthcare 
professionals participate in supporting medicine users in managing and 
monitoring their medications. The Rational Pharmacotherapy Action Plan 
places an emphasis on partnership, multidisciplinary cooperation, recording 
the objectives and monitoring of pharmacotherapy agreed with individual 
medicine users in their client care plans, and the personal responsibility of each 
healthcare professional for updating the medication lists. 
Doctors will ensure that medications and their effectiveness are reviewed regularly as 
a whole, especially when it comes to frequent users of services or medications, and 
that medications are managed as a whole and carried out so as to avoid any 
unnecessary costs in terms of both patients and society. Pharmacotherapy that is 
planned, implemented and monitored well forms part of comprehensive patient care.  
Together with each patient, doctors will ensure that medications as a whole are 
appropriate with regard to the patient’s current needs, characteristics and possibilities. 
The choice of medicine will be primarily based on research evidence validating the 
efficacy and safety of the medicine, care guidelines or approved clinical practice. The 
medicines prescribed are cost-effective. Doctors receive feedback on their 
prescription practices. 
Doctors will ensure that the regimen of medications and the plan for the 
implementation of care agreed with each patient are recorded in the client care plan, 
that the medicine list is up to date, and that information on the regimen of medications 
is forwarded as required. The monitoring and self-management of medications will be 
agreed with the patient.  
Pharmacists will support the implementation of safe and cost-effective 
pharmacotherapy through counselling when dispensing medicines, while also 
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monitoring the appropriate implementation of medications and referring medicine 
users to see a doctor as required. Where necessary, pharmacists will participate in 
multidisciplinary medication reviews and support patients with rational self-medication. 
The healthcare professionals involved in treating individual patients will support 
medicine users to ensure that they know how and why they are using the prescribed 
medicines, while also taking medicine users’ individual wishes into account. They will 
also monitor the achievement of the objectives of pharmacotherapy together with the 
medicine users, while encouraging users to play an active role in managing their own 
therapy and to provide information on any effects of their medications that they may 
observe. Cooperation between different professionals and individual medicine users 
will be smooth. 
Each professional’s pharmacotherapeutic competencies will correspond to their duties 
in the pharmacotherapy process. Continuing professional development will maintain 
pharmacotherapeutic competencies and, consequently, medication safety. Healthcare 
and social welfare professionals will possess sufficient knowledge and skills to 
provide medicine users with medication and self-management counselling and to use 
digital tools. 
OBJECTIVES TO BE ACHIEVED BY 2022 
• Doctors will agree with each medicine user on the regimen of 
medications, implementation and monitoring of pharmacotherapy, and 
on recording these in the client care plan as part of other care.  
• Healthcare professionals responsible for treating patients will monitor 
the achievement of the objectives of pharmacotherapy together with 
medicine users, making use of the opportunities provided by 
digitalisation. Other healthcare professionals and pharmacists will 
support and monitor the implementation of pharmacotherapy together 
with medicine users.  
• The medications in use will be cost-effective from the perspectives of 
both medicine users and society. 
• Every medicine user, especially frequent service users with multiple 
illnesses and medications, will be provided with an up-to-date client care 
plan and medication list drawn up and maintained together with a 
healthcare professional. 
• Healthcare and social welfare professionals will also possess 
competencies required to make use of electronic decision support 
systems and medicines information. 
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REPORTS AND STUDIES INCLUDED IN THE ACTION PLAN 
Rationaalinen lääkkeen määrääminen, toimittaminen ja käyttö nykyisissä ja tulevissa 
sote-rakenteissa. Työryhmän raportti. Sosiaali- ja terveysministeriön raportteja ja 
muistioita 12/2018.  
[Rational prescribing, dispensing and use of medicines in current and future 
healthcare and social welfare structures. Working group report. Reports and 
Memorandums of the Ministry of Social Affairs and Health12/2018.] 
Available in Finnish at: http://urn.fi/URN:ISBN:978-952-00-3912-7 
Rationaalisen lääkehoidon tiedonhallinnan kehittäminen. Työryhmän raportti. Sosiaali- 
ja terveysministeriön raportteja ja muistioita 11/2018.  
[Development of data management to support rational pharmacotherapy. Working 
group report. Reports and Memorandums of the Ministry of Social Affairs and Health 
11/2018.] 
Available in Finnish at: http://urn.fi/URN:ISBN:978-952-00-3911-0 
Kiviluoto K: Selvitys keinoista lääkkeenmääräämisen järkevöittämiseksi viidessä 
esimerkkimaassa. Julkaisematon raportti, Sosiaali- ja terveysministeriö 2016. 
[Kiviluoto K: A report on the means of rationalising medication prescription practices in 
five example countries. Unpublished report, Ministry of Social Affairs and Health 
2016.] 
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5 Medicine users will use 
pharmaceuticals rationally and as 
agreed 
Objective for medicine users and their family and friends 
Medicine users must have a clear understanding of their medications as a 
whole and of why and how medicines are used. For this purpose, they need 
medicines information and support from healthcare and social welfare 
professionals. The Rational Pharmacotherapy Action Plan places an emphasis 
on partnership between medicine users and healthcare and social welfare 
professionals and medicine users’ own responsibility for implementing their 
pharmacotherapy. An up-to-date medication list is a tool that helps a medicine 
user manage the whole and discuss with healthcare and social welfare 
professionals. 
Medicine users will agree with their attending physicians on the regimen of 
medications, implementation and monitoring of therapy, and on recording these in 
their personal client care plan. Medicine users will be responsible for carrying out their 
own pharmacotherapy in an appropriate manner and for achieving its objectives, 
within the limits of their own resources (Figure 2). If a medicine user is unable to take 
responsibility for their own regimen of medications, the responsibility will be assigned 
to an individual, such as a family member or friend, whose identity is known to the 
healthcare and social welfare service units involved in treating the user. 
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Figure 2. Tasks of patients and healthcare and social welfare professionals in community care settings at different 
stages of the pharmacotherapy process. The pharmacotherapy process and, accordingly, the tasks involved will be 
different when pharmacotherapy is carried out in settings such as healthcare or social welfare service units. 
Medicine users will use pharmaceuticals as agreed. Medicine users will bear their 
own share of responsibility for avoiding unnecessary costs and medicine wastage by 
means such as only buying the amount of medicine that they require and 
understanding that they must not hand over their medicines to others, consequently 
contributing to medication safety, cost-effectiveness and ecological considerations. 
Medicine users will participate in keeping their own medication list up to date. They 
may ask whether their medication list is up to date while seeing healthcare 
professionals, for example, and inform professionals of any over-the-counter (OTC) 
medicines, food supplements or other medicinal products that they may use. 
Medicine users will actively share their individual wishes and concerns relating to 
pharmacotherapy with healthcare and social welfare professionals. They will also 
actively ask about any aspects of their pharmacotherapy that may remain unclear and 
obtain reliable information on medicines while visiting healthcare and social welfare 
service units or pharmacies. Subject to each medicine user’s consent, all their 
medication data will be accessible to everyone involved in pharmacotherapy. 
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New digital service channels and applications will support medicine users in 
implementing and monitoring rational pharmacotherapy. Citizens will have access to 
electronic services and be able to produce information for themselves and for use by 
professionals. The national My Kanta Pages service at omakanta.fi allows citizens to 
view their own electronic prescriptions, dispensing events, and summaries of their 
patient records. In the future, they will also be able to add their own entries relating to 
pharmacotherapy, for example, to the service. Reliable sources of information and 
client-oriented digital services will support rational pharmacotherapy. Online 
pharmacy services will be smooth to use. Where required, the national digital self-
management pathway will lead to reliable online pharmacy services. 
OBJECTIVES TO BE ACHIEVED BY 2022 
• Medicine users will be increasingly supported in assuming responsibility 
for carrying out their own pharmacotherapy in an appropriate manner, 
within the limits of their own resources and possibilities. 
• Medicine users or their family and friends will agree with the attending 
physician on the regimen of medications, and on the implementation 
and monitoring of medications.  
• National medication lists will be widely used. Medicine users (or family 
members or friends in charge of pharmacotherapy) will update the 
national register with details of their own medication data, such as use 
of over-the-counter (OTC) medicines. 
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Appendix 1: Descriptions of working group 
operations 
1. Working group for prescription, dispensation and use of medicines 
The working group on prescribing medicines carried out preparatory work in support 
of implementing rational pharmacotherapy, especially from the perspective of rational-
ising the practices relating to prescription of medicines. The key areas identified for 
improvement included curbing medicine costs, promoting medication safety through 
means such as enhancing access to up-to-date medication data and comprehensive 
medication management, and steering and supporting pharmacotherapy decisions 
made by prescribers. The working group already carried out measures aiming to bring 
solutions to most of these areas while planning the implementation of the Action Plan 
(2016–2017). 
Actions: 
− participating in drafting legislative amendments;  
− promoting the uptake of biosimilars, with primary responsibility for 
drawing up and implementing a plan on biosimilars to promote the 
introduction of biosimilars; 
− preparing a communication campaign for healthcare professionals, 
especially drawing up a poster entitled ‘Elements of rational 
pharmacotherapy’;  
− carrying out preparatory work to increase feedback for prescribers.  
The working group for dispensing medicines focused on promoting the introduction of 
biosimilars, reducing unnecessary medicine purchases and medicine wastage, and 
improving comprehensive medication management. 
Actions: 
− The working group participated in drawing up a plan to promote the 
introduction of biosimilars, a multidisciplinary operating model and 
informative guidance for pharmacies. 
− As part of updating Administrative Regulation No. 2/2016 issued by the 
Finnish Medicines Agency (Fimea) on dispensing medicines, the group 
specified provisions on indicating the remaining amounts of medicines 
on prescriptions and on small medicine packaging to be dispensed at 
the beginning of long-term pharmacotherapy, etc. At the same time, the 
Administrative Regulation was revised to align with the amendments to 
PUBLICATIONS OF THE MINISTRY OF SOCIAL AFFAIRS AND HEALTH XX/201X 
 
31 
 
 
Decree 1088/2010 issued by the Ministry of Social Affairs and Health on 
the prescription of medicines, which entered into force at the same time. 
− A sub-group of the working group began deliberations on the criteria for 
reviewing medications, which would refer patients to medication review 
services in a targeted manner (a register-based model built on a 
screening tool). 
− Furthermore, the sub-group drew up a proposal for more efficient 
monitoring of the success of pharmacotherapy through development of 
cooperation and communication between pharmacies and physicians. 
The working group for the use of medicines concentrated on supporting patients and 
medicine users in implementing rational pharmacotherapy and managing medications 
as a whole as well as on providing information on biosimilars.  
Actions: 
− promoting the use of client care plans and up-to-date medication lists as 
part of a public awareness campaign named ‘Suitable Medicine’ 
included in the Rational Pharmacotherapy Action Plan; 
− providing information for patient groups using biopharmaceuticals and 
biosimilars at a seminar entitled ‘Biosimilars – for me?’ held on 17 May 
2017, as well as in articles appearing in magazines published by patient 
organisations. 
Report by the working group for prescribing, dispensing and use of medicines: 
Rationaalinen lääkkeen määrääminen, toimittaminen ja käyttö nykyisissä ja tulevissa 
sote-rakenteissa. Työryhmän raportti. Sosiaali- ja terveysministeriön raportteja ja 
muistioita 12/2018.  
[Rational prescribing, dispensing and use of medicines in current and future 
healthcare and social welfare structures. Working group report. Reports and 
Memorandums of the Ministry of Social Affairs and Health 12/2018.]  
Available in Finnish at: http://urn.fi/URN:ISBN:978-952-00-3912-7 
2. Working group for pharmaceutical services structures as part of the health 
and social services reform 
The working group’s work was affected by incomplete legislation on the health and 
social services reform. Within the working group’s term, it was challenging to 
implement the assignment recorded in the interim report of the Rational 
Pharmacotherapy Action Plan, namely, how to make financing structures and 
responsibilities, citizens’ freedom of choice in services and digital service models 
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support rational pharmacotherapy in the best possible way. It was not possible to go 
through the details of legislative amendments governing pharmaceutical services at a 
concrete level. Instead, the working group’s work provided context, focusing on 
identifying current problems and alternative solutions. In its work, the group 
concentrated on hospital pharmacy activities and on defining the rational 
pharmacotherapy process. 
Report by the working group for the pharmaceutical services structures as part of the 
health and social services reform: 
Lääkehuolto sote-toimintaympäristössä. Työryhmän raportti. Sosiaali- ja 
terveysministeriön raportteja ja muistioita 6/2018. 
[Pharmaceutical services in the operating environment of health and social services. 
Working group report. Reports and Memorandums of the Ministry of Social Affairs and 
Health 6/2018.]  
Available in Finnish at: http://urn.fi/URN:ISBN:978-952-00-3903-5 
3. Working group for assessment of the therapeutic and economic value of 
medicines 
The working group was tasked with finding out how assessment of the therapeutic 
and economic value of medicines should be organised in Finland in the future. 
Actions: 
The working group’s output was a report, which aimed to:  
1. collect the points to consider when planning assessment of the 
therapeutic and economic value of medicines; 
2. describe the current status of assessment of the therapeutic and 
economic value of medicines in Finland; 
3. identify the primary areas for improvement in the current system; 
4. propose national objectives for health technology assessments of 
pharmaceuticals;  
5. propose a national model for health technology assessments of 
pharmaceuticals; 
6. estimate the resources and financing required for health technology 
assessments of pharmaceuticals; 
7. determine any further aspects relating to health technology 
assessments of pharmaceuticals that may need to be studied. 
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Objectives 4 to 6 concern health technology assessments of pharmaceuticals used in 
public healthcare services. In this context, a medicine used in public healthcare refers 
to cases where a medicine is primarily intended for use in hospitals operating within 
the public healthcare sector or is primarily purchased in Finland by hospitals, or where 
the use or reconstitution of a medicine generally requires hospital conditions. The 
definition also covers medications for generally hazardous and notifiable 
communicable diseases. 
Report by the working group for assessment of the therapeutic and economic value of 
medicines  
Pelkonen L, Rannanheimo P, Anttila V-J, Komulainen J, Koskinen H, Leipälä J, ym. 
Miten lääkkeiden hoidollisen ja taloudellisen arvon arviointi tulisi järjestää Suomen 
sosiaali- ja terveydenhuollossa? Rationaalisen lääkehoidon toimeenpano-ohjelman 
asiantuntijaryhmän selvitys. Sosiaali- ja terveysministeriön raportteja ja muistioita 
2017:31.  
[Pelkonen L, Rannanheimo P, Anttila V-J, Komulainen J, Koskinen H, Leipälä J, et al. 
How should the assessment of the therapeutic and economic value of medicines be 
organised in Finland's healthcare and social welfare services? Study by an expert 
group for the Rational Pharmacotherapy Action Plan. Reports and Memorandums of 
the Ministry of Social Affairs and Health 2017:31.]  
Available in Finnish at: http://urn.fi/URN:ISBN:978-952-00-3881-3  
4. Working group for research into rational pharmacotherapy 
The working group on research explored the current status of and preconditions for 
research relating to rational pharmacotherapy, while also outlining some research 
themes for the future. Furthermore, the group supported the work of the other working 
groups of the Rational Pharmacotherapy Action Plan by compiling and communicating 
research data to inform their work. 
Actions: 
− organising two research seminars on rational pharmacotherapy, on 23 
November 2016 and 22 November 2017; 
− drawing up a research strategy for rational pharmacotherapy with the aid 
of extensive cooperation with stakeholders; 
− putting together and launching a research network for rational 
pharmacotherapy; 
PUBLICATIONS OF THE MINISTRY OF SOCIAL AFFAIRS AND HEALTH XX/201X 
 
34 
 
 
− producing compilations of domestic and international research to meet 
the information needs identified by the other working groups of the 
Rational Pharmacotherapy Action Plan. 
Research strategy for rational pharmacotherapy: 
Tutkimustieto hyötykäyttöön: Rationaalisen lääkehoidon tutkimusstrategia 2018–2022. 
Sosiaali- ja terveysministeriön raportteja ja muistioita 7/2018. 
[Effective use of research data: Research strategy for rational pharmacotherapy 
2018–2022.Reports and Memorandums of the Ministry of Social Affairs and Health 
7/2018.] 
Available in Finnish at: http://urn.fi/URN:ISBN:978-952-00-3905-9 
5. Working group for pharmaceutical innovations 
Pharmaceutical development requires special expertise in several disciplines and 
understanding of pharmaceutical development processes and legislative frameworks. 
This is why the commercial potential of findings made in Finnish universities is often 
left untapped. The pharmaceutical innovation working group deliberated on both the 
opportunities for and challenges to success with a view to promoting the utilisation of 
pharmaceutical innovations in Finland. 
The pharmaceutical innovations working group started operations in November 2016 
by organising a discussion meeting entitled ‘Pharmaceutical research as part of the 
Health Sector Growth Strategy for Research and Innovation Activities’. Its actual work 
commenced in January 2017. As part of the Rational Pharmacotherapy Action Plan, 
the Ministry of Social Affairs and Health commissioned a preliminary study on the 
establishment of a National Pharmaceutical Development Centre as part of 
implementing the Roadmap for the Health Sector Growth Strategy for Research and 
Innovation Activities in early 2017 (Esiselvitys: Kansallinen lääkekehityskeskus 
[Preliminary study: National Pharmaceutical Development Centre], by Erkki Palva). In 
June 2017, the Ministry of Economic Affairs and Employment and the Ministry of 
Social Affairs and Health organised a seminar relating to the Growth Strategy, 
focusing on creating an innovation environment for pharmaceutical development. 
As a result of the discussions, it was deemed necessary to continue considering the 
establishment of a National Pharmaceutical Development Centre to support 
pharmaceutical development activities. In its report, the working group outlines its 
vision for the National Pharmaceutical Development Centre. 
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Report by the pharmaceutical innovation working group: 
Kansallinen lääkekehityskeskus. Lääkeinnovaatiot työryhmän raportti. Sosiaali- ja 
terveysministeriön raportteja ja muistioita 5/2018.  
[National Pharmaceutical Development Centre. Report by the Pharmaceutical 
Innovation Working Group. Reports and Memorandums of the Ministry of Social 
Affairs and Health 5/2018.]  
Available in Finnish at: http://urn.fi/URN:ISBN:978-952-00-3902-8 
6. Ad hoc working group for data management 
As part of working on the Rational Pharmacotherapy Action Plan, each working group 
involved in drawing up the Action Plan familiarised itself with ongoing data 
management projects from the perspective of its own theme and identified the data 
required to promote rational pharmacotherapy. In February, an ad hoc working group 
was set up to work on data management, aiming to collect details of the data 
requirements of rational pharmacotherapy. The ad hoc working group compiled an 
overview of national ICT service packages for health and social services and 
examined it from the perspective of pharmacotherapy. The data management needs 
of the Action Plan were prioritised on the basis of national objectives and project 
priorities. The working group focused its work on the following two themes: data 
management at the level of 1) individuals and 2) providers. The first theme deals with 
a project to develop an up-to-date national medication list, the possibilities of medicine 
users to enter their own medication data into the My Kanta Pages service and use a 
digital care pathway, as well as the possibilities of citizens and healthcare 
professionals to recognise problems in pharmacotherapy. The latter theme explores 
how to produce indicators for pharmacotherapy and pharmaceutical services to meet 
steering and supervision needs and to assess the effectiveness of new medicines, for 
example. In addition, the working group compiled areas for improvement relating to 
the functionalities of various systems. The purpose of its work was to ensure that the 
existing projects pay attention to aspects relevant to the Rational Pharmacotherapy 
Action Plan. 
Report by the ad hoc working group for data management: 
Rationaalisen lääkehoidon tiedonhallinnan kehittäminen. Työryhmän raportti. Sosiaali- 
ja terveysministeriön raportteja ja muistioita 11/2018.  
[Development of data management to support rational pharmacotherapy. Working 
group report. Reports and Memorandums of the Ministry of Social Affairs and Health 
11/2018.] 
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Available in Finnish at: http://urn.fi/URN:ISBN:978-952-00-3911-0 
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